Archives of Cardiovascular Diseases最新文献

{"title":"","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":"119 1","pages":"Page S33"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146474629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":"119 1","pages":"Pages S42-S43"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146474646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":"119 1","pages":"Page S45"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146474650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":"119 1","pages":"Pages S54-S55"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146474664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mental health as a predictor of cardiovascular outcomes in coronary artery disease","authors":"Y. Ayadi ,&nbsp;S. Charfeddine ,&nbsp;A. Ghrab ,&nbsp;M. Jabeur ,&nbsp;T. Ellouze ,&nbsp;R. Gargouri ,&nbsp;Z. Triki ,&nbsp;F. Triki ,&nbsp;A. Bahloul ,&nbsp;L. Abid","doi":"10.1016/j.acvd.2025.10.029","DOIUrl":"10.1016/j.acvd.2025.10.029","url":null,"abstract":"<div><h3>Introduction</h3><div>Psychological distress—such as anxiety, depression, and stress—is common in coronary artery disease (CAD) and contributes to worse outcomes, yet it is often overlooked in standard cardiac care.</div></div><div><h3>Objective</h3><div>To assess the relationship between mental health disorders and clinical outcomes in CAD patients, and to compare findings between acute coronary syndrome (ACS) and chronic coronary syndrome (CCS) groups.</div></div><div><h3>Method</h3><div>This prospective study was conducted between Novembre 2023 and April 2025 at the Department of Cardiology in a tertiary care center. We included patients with CAD admitted for ACS, those undergoing coronary angiography (CAG) for CCS, and patients seen in routine follow-up. Stress, anxiety, and depression were assessed using the PSS, GAD-7, and PHQ-9 scales, respectively. We aim to compare the characteristics of the two groups: ACS and CCS. Patients were followed for a period ranging from 9 months to 1 year after inclusion. Major adverse cardiovascular events (MACE) were recorded. Psychological scores were monitored over the follow-up period.</div></div><div><h3>Results</h3><div>This study included 51 patients with a mean age of 57.86 years. No significant differences were found between the ACS and CCS groups regarding Cardiovscular Risk Factors. However, sedentarity was more prevalent in the CCS group (<em>P</em> <!-->=<!--> <!-->0.03). Both anxiety (GAD-7<!--> <!-->≥<!--> <!-->9) (<em>P</em> <!-->=<!--> <!-->0.024) and depression (PHQ-9<!--> <!-->≥<!--> <!-->9) (<em>P</em> <!-->=<!--> <!-->0.020) were significantly more prevalent in the ACS group than in the CCS group, whereas stress levels (PSS<!--> <!-->≥<!--> <!-->15), although higher in ACS, did not differ significantly (<em>P</em> <!-->=<!--> <!-->0.44) (<span><span>Fig. 1</span></span>). Over the 9–12-month follow-up, the prevalence of depression, anxiety and stress declined. However, persistent depression was significantly associated with major adverse cardiovascular outcomes (ACVo) (<em>P</em> <!-->=<!--> <!-->0.041) while anxiety and stress were not (<em>P</em> <!-->=<!--> <!-->0.43 and 0.59, respectively). Treatment non-adherence tended to cluster with psychological distress—83%had at least one elevated score—but this trend did not reach statistical significance (<em>P</em> <!-->=<!--> <!-->0.13).</div></div><div><h3>Conclusion</h3><div>CAD patients, particularly with ACS, face significant psychological challenges. Persistent depression predicts ACVo. Mental health integration in CAD care may improve overall prognosis, warranting further research.</div></div>","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":"119 1","pages":"Page S19"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145903915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PHM Ratio < 0.82 predicts mortality after heart transplant: Evidence from the French CRISTAL Cohort","authors":"A. Buschiazzo ,&nbsp;G. Lebreton ,&nbsp;R. Dorent ,&nbsp;E. Flécher ,&nbsp;A. Vincentelli ,&nbsp;J.-C. Roussel ,&nbsp;T. Senage ,&nbsp;C.-H. David","doi":"10.1016/j.acvd.2025.10.056","DOIUrl":"10.1016/j.acvd.2025.10.056","url":null,"abstract":"<div><h3>Introduction</h3><div>Predicted heart Mass (PHM) is recommended to assess donor-recipient size matching and predict mortality after heart transplant, based on the UNOS Cohort. UNOS and French cohort presents differences regarding donors and recipients. UNOS and French cohort presents differences regarding donors and recipients.</div></div><div><h3>Objective</h3><div>To ensure that PHM accurately predicts mortality following heart transplant in France, we assessed survival according to PHM ratio, compared to conventional metrics, in the French cohort.</div></div><div><h3>Method</h3><div>We analyzed data from the CRISTAL registry (2000–2018), including 5091 heart transplant recipients. For each matching metric, the cohort was divided into 11 equal strata. Survival was assessed at 1 month and 3 years using Kaplan-Meier estimators. Multivariate Cox models were used to compute hazard ratios.</div></div><div><h3>Results</h3><div>A PHM ratio<!--> <!-->&lt;<!--> <!-->0.825 was associated with significantly increased 1-month mortality (HR 1.45; 95% CI 1.09–2.03; <em>P</em> <!-->=<!--> <!-->0.044) and 3-year mortality (HR 1.21; 95% CI 1.05–1.39; <em>P</em> <!-->=<!--> <!-->0.001). No other size-matching metric showed increased risk at 1 month. At 3 years, undersized BSA ratio was also associated with higher mortality (HR 1.66; 95% CI 1.15–2.40; <em>P</em> <!-->=<!--> <!-->0.034), while other metrics were not significant (<span><span>Fig. 1</span></span>).</div></div><div><h3>Conclusion</h3><div>The PHM ratio is a robust predictor of post-transplant mortality in the French population. We identified a lower threshold (&lt;<!--> <!-->0.82) than previously reported, which could enhance donor-recipient matching strategies in France.</div></div>","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":"119 1","pages":"Page S31"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145903939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular diagnostic classification for heart allograft rejection: A validated and automated system","authors":"G. Coutance ,&nbsp;A. Giarraputo ,&nbsp;J. Patel ,&nbsp;M. Fedrigo ,&nbsp;S. Varnous ,&nbsp;J.-P. Duong ,&nbsp;J. Dagobert ,&nbsp;P. Rouvier ,&nbsp;P. Leprince ,&nbsp;P. Achouh ,&nbsp;X. Jouven ,&nbsp;P. Bruneval ,&nbsp;A. Angelini ,&nbsp;J. Kobashigawa ,&nbsp;A. Loupy","doi":"10.1016/j.acvd.2025.10.058","DOIUrl":"10.1016/j.acvd.2025.10.058","url":null,"abstract":"<div><h3>Introduction</h3><div>Endomyocardial biopsies (EMB) gene expression profiling is a promising companion tool for rejection diagnosis after heart transplantation. We developped and validated a tissular-based molecular diagnostic system of cardiac allograft rejection.</div></div><div><h3>Objective</h3><div>Our aim to design an automated report accessible for routine application in clinical practice to support diagnosis of rejection after heart transplantation.</div></div><div><h3>Method</h3><div>We performed a multicenter, retrospective study (<span><span>NCT06436027</span><svg><path></path></svg></span>), collecting 591 FFPE-EMBs between 2011 and 2021 representative of the landscape of rejection (antibody-mediated rejection-AMR, <em>n</em> <!-->=<!--> <!-->188; acute cellular rejection-ACR, <em>n</em> <!-->=<!--> <!-->289; non-rejection, <em>n</em> <!-->=<!--> <!-->114). Tissue gene expression was analyzed using the consensus Banff Human Organ Transplant gene panel. Molecular classifiers for AMR and ACR were built using a supervised model, assessing thoroughly the performance. An automated molecular report was developed to provide a comprehensive visualization for clinical use.</div></div><div><h3>Results</h3><div>In the validation cohort (<em>n</em> <!-->=<!--> <!-->116), the molecular classifiers demonstrated strong diagnostic performance: AMR detection achieved an accuracy of 81.89% (ROC-AUC<!--> <!-->=<!--> <!-->0.831, Brier score<!--> <!-->=<!--> <!-->0.143), while ACR detection achieved 77.58% accuracy (ROC-AUC<!--> <!-->=<!--> <!-->0.812, Brier score<!--> <!-->=<!--> <!-->0.176). The molecular report provided real-time assessment of molecular-based rejection scores, while allowing to contextualize a novel biopsy within the reference set rejection landscape (<span><span>Fig. 1</span></span>). In addition to delivering quantitative scores for AMR and ACR, clinical and biological information are recapitulated in each report, correlating the molecular findings with the pathophysiological insights from primary molecular pathways involved. This tool captured subtle molecular signals in cases of early or sub-clinical rejection, offering insights into potential risks even when histology was inconclusive. The automated nature of the report minimizes variability and considerably reduces turnaround time, seamlessly integrating into clinical workflows.</div></div><div><h3>Conclusion</h3><div>The molecular diagnostic system, validated and supported by an automated report, demonstrated high reproducibility and reliability in identifying cardiac rejection. This system can complement standard pathology, reduce diagnostic uncertainty, and serve as a practical companion tool in the clinical management of heart transplant patients, ensuring timely and accurate diagnosis.</div></div>","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":"119 1","pages":"Pages S32-S33"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145903941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early introduction of SGLT2 inhibitors in patients with Heart Failure reduced ejection fraction hospitalized for acute heart failure: Results from Real-world observations","authors":"A. Bouchlarhem,&nbsp;Z. Bazid,&nbsp;N. Ismaili,&nbsp;E.O. Noha","doi":"10.1016/j.acvd.2025.10.080","DOIUrl":"10.1016/j.acvd.2025.10.080","url":null,"abstract":"<div><h3>Introduction</h3><div>The early introduction of SGLT2 inhibitors during acute heart failure was studied in the empulse trial with positive results, but limited reel-world data are currently available.</div></div><div><h3>Objective</h3><div>Assessing the efficacy of early introducing of ISGLT2 during the acute heart failure.</div></div><div><h3>Method</h3><div>We prospectively analyzed patients admitted for acute heart failure with an ejection fraction of less than 40%. We excluded patients with glomerular filtration rate (GFR)<!--> <!-->&lt;<!--> <!-->20<!--> <!-->ml/min, cardiogenic shock, and ejection fraction<!--> <!-->&gt;<!--> <!-->40%. We studied all-cause mortality as the primary outcome, and as secondary outcomes the duration of decongestion and pro-BNP levels at discharge.</div></div><div><h3>Results</h3><div>We included 516 patients who met the inclusion criteria. Early introduction of ISGLT2 was adopted in 270 patients (52.8%). No differences were observed in mean age (ISGLT vs. standard car;65.89 vs 65.58 years; <em>P</em> <!-->=<!--> <!-->0.129), female gender (38.9% vs. 38.2%; <em>P</em> <!-->=<!--> <!-->0.473), diabetes (48.1% vs. 51.6%; <em>P</em> <!-->=<!--> <!-->0.242) and hypertension (44.4% vs. 45.5%; <em>P</em> <!-->=<!--> <!-->0.437). At admission, Ejection fraction was higher in the ISGLT2 group (34% vs. 32%; <em>P</em> <!-->=<!--> <!-->0.033), and systolic pulmonary pressure was lower (37.4mmhg vs. 41.5mmhg; <em>P</em> <!-->&lt;<!--> <!-->0.001).GFR was higher in the ISGLT2 group (72 vs 64<!--> <!-->ml/min; <em>P</em> <!-->=<!--> <!-->0.005), with lower Pro-BNP levels in this group but without significant difference (7635 vs 9839<!--> <!-->ng/ml; <em>P</em> <!-->=<!--> <!-->0.063).</div><div>Over a mean follow-up of 22 months, the primary endpoint was observed in 95 patients (18.4%), with significantly higher mortality in the standard group (28.5% vs. 9.3%; <em>P</em> <!-->&lt;<!--> <!-->0.001). After multivariate adjusted Cox proportional hazards analysis, early introduction of ISGLT2 was independently associated with a 23% reduction in all-cause mortality with (HR: 0. 862; 95%CI; 0.444–0.902; <em>P</em> <!-->=<!--> <!-->0.039), as well as a significant difference on Kaplein meirer survival analysis (Log-rank test <em>P</em> <!-->&lt;<!--> <!-->0.001) (<span><span>Fig. 1</span></span>). For the secondary endpoints, the introduction of ISGLT2 significantly reduced the duration of decongestion (6.25 days in vs. 7.37 days; <em>P</em> <!-->=<!--> <!-->0.017; with a mean reduction of 1.17 days). ISGLT2 also significantly reduced Pro-BNP levels at discharge (3986 vs. 7029<!--> <!-->ng/ml; <em>P</em> <!-->=<!--> <!-->0.001).</div></div><div><h3>Conclusion</h3><div>The results of our study support the hypothesis that SGLT2 should not only be introduced in HFrEF patients, but should also be rapidly introduced even during acute heart failure.</div></div>","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":"119 1","pages":"Page S46"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145904046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiac amyloidosis and heart failure phenotypes: A prognostic study of systolic function markers","authors":"A. Zaroui ,&nbsp;S. Belaid ,&nbsp;M. Kharoubi ,&nbsp;S. Oghina ,&nbsp;S. Odouard ,&nbsp;E. Teiger ,&nbsp;T. Damy","doi":"10.1016/j.acvd.2025.10.086","DOIUrl":"10.1016/j.acvd.2025.10.086","url":null,"abstract":"<div><h3>Introduction</h3><div>Cardiac amyloidosis (CA), including light chain (AL), hereditary transthyretin (ATTRv), and wild-type transthyretin (ATTRwt), leads to heart failure (HF). Cardiologists use the ESC guidelines to classify patients with HF tailoring HF treatment accordingly. CA is commonly associated with HFpEF, with a smaller proportion presenting with HFmrEF and HFrEF.</div></div><div><h3>Objective</h3><div>This study aimed to assess the distribution of HF types in CA and their relationship with other left ventricular (LV) systolic function parameters such as global longitudinal strain (GLS) and cardiac index (CI) across amyloidosis subtypes.</div></div><div><h3>Method</h3><div>We retrospectively included symptomatic AL, ATTRv, and ATTRwt CA patients from our French referral center. LVEF was classified per ESC guidelines and compared to GLS and CI. Survival was assessed using Kaplan-Meier analyses and Cox regression. A decision tree incorporating LVEF, GLS, and CI was used to stratify patients into prognostic groups.</div></div><div><h3>Results</h3><div>Among 2244 patients, 557 AL, 392 ATTRv, 1137A TTRwt. Of these, 61.4% presented with HFpEF, 19.0% with HFmrEF, and 19.6% with HFrEF. In AL, 13.6%, 18%, and 68.4% were classified as HFrEF, HFmrEF, and HFpEF, respectively. In ATTRv, 28.3%, 15.3%, and 56.4% were HFrEF, HFmrEF, and HFpEF, respectively. In ATTRwt, 20.2%, 21.2%, and 58.6% were HFrEF, HFmrEF, and HFpEF, respectively. LVEF correlated moderately with GLS (<em>r</em> <!-->=<!--> <!-->0.673), with stronger correlations in ATTRv (<em>r</em> <!-->=<!--> <!-->0.776) compared to AL (<em>r</em> <!-->=<!--> <!-->0.650) and ATTRwt (<em>r</em> <!-->=<!--> <!-->0.644). LVEF correlated weakly with CI (<em>r</em> <!-->=<!--> <!-->0.392). Median survival was 7 months [3–31] for AL, 28 months [12–54] for ATTRv, and 23 months [10–38] for ATTRwt. Survival differed by HF type: 30 months [18–41] for HFrEF, 40 months [20–42] for HFmrEF, and 51% survival at 48 months for HFpEF. A CI<!--> <!-->≤<!--> <!-->1.96<!--> <!-->L/min/m² was associated with a median survival of 29 months [17–37], with better outcomes in higher CI quartiles. A decision tree identified four prognostic groups, with hazard ratios for 4-year mortality ranging from 1.63 (LVEF<!--> <!-->≥<!--> <!-->50%, GLS<!--> <!-->≤<!--> <!-->11%) to 3.68 (LVEF<!--> <!-->≤<!--> <!-->49%, CI<!--> <!-->≤<!--> <!-->1.96 L/min/m²), reaching 12.34 in AL amyloidosis for the most severe group.</div></div><div><h3>Conclusion</h3><div>In CA, about 40% of patients present with reduced LVEF. Cardiologists should be aware that CA is not exclusively associated with HFpEF and that patients with reduced LVEF have worse prognosis. LV systolic function, assessed via LVEF, GLS, and CI, is a critical predictor of survival in CA, with distinct patterns across AL, ATTRv, and ATTRwt subtypes.</div></div>","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":"119 1","pages":"Page S49"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145904061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of telemonitoring implementation on heart failure hospitalization profiles: A real-world analysis","authors":"P. Lemiere ,&nbsp;J. Quilici ,&nbsp;A.-S. Canu ,&nbsp;L. Querion ,&nbsp;E. Saunier ,&nbsp;A. Vaudron","doi":"10.1016/j.acvd.2025.10.090","DOIUrl":"10.1016/j.acvd.2025.10.090","url":null,"abstract":"<div><h3>Introduction</h3><div>Heart failure (HF) remains a leading cause of hospitalization and mortality worldwide. Remote monitoring programs (RMP) are increasingly implemented to optimize care, yet their real-world impact on hospitalized patient characteristics remains underexplored.</div></div><div><h3>Objective</h3><div>This study aimed to assess changes in the clinical profiles and outcomes of patients hospitalized for acute heart failure (AHF) before and after the implementation of a RMP in a rural cardiology department.</div></div><div><h3>Method</h3><div>We conducted a retrospective, single-center, study focusing HF-related hospitalizations (HFRH) in two periods: 2018–2019 with standard care; and 2023–2024 post RMP implementation, combining non-invasive remote weight monitoring, therapeutic education, and early home-based intervention by a mobile HF team. Data were extracted using ICD-10 codes.</div></div><div><h3>Results</h3><div>Among 4092 admissions, we selected 1364 HFRH (610 in 2018–2019 vs. 754 in 2023–2024), patients in the post RMP period showed higher severity (High GHM levels 51.5% vs. 45.6%, <em>P</em> <!-->=<!--> <!-->0.031; mean IGS2 score: 37.7 vs. 35.1, <em>P</em> <!-->&lt;<!--> <!-->0.0001), longer hospital stays (mean 9.5 vs. 8.9 days, <em>P</em> <!-->&lt;<!--> <!-->0.001), more emergency admissions (66.6% vs. 39.4%, <em>P</em> <!-->&lt;<!--> <!-->0.0001), non-significant increased mortality (6.1% vs 3.9%, <em>P</em> 0.07). However, rehospitalizations decreased (13.4% vs. 18.1%, <em>P</em> <!-->=<!--> <!-->0.03), and discharges to home increased (61.0% vs. 49.3%, <em>P</em> <!-->&lt;<!--> <!-->0.0001) (<span><span>Fig. 1</span></span>).</div></div><div><h3>Conclusion</h3><div>The implementation of the RMP improved post-discharge outcomes and was associated with a shift toward hospitalization of more severe heart failure patients, likely reflecting earlier outpatient management of milder cases. These findings support telemonitoring as an effective tool in real-world heart failure management and underscore its role in the ongoing digital transformation of care pathways.</div></div>","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":"119 1","pages":"Page S51"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145904072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}